Blog

Recent publications, including a landmark paper from Novartis¹, demonstrate the viability and utility of cryopreserved leukopaks, dispelling the viability myth.

Cryopreserved leukopaks eliminate the constraints imposed by a reliance on fresh human cells for T-cell therapies. Has the tide turned in favor of frozen cells?

This March 2022, while we celebrate Women’s History Month, we pay tribute to women whose incredible achievements have advanced science, medicine, and technology.  The National Women’s History Alliance’s theme for this ...

Access to highly-annotated primary human tissues is an integral part of precision medicine research and development, but the logistical barriers of acquiring fresh tissue have persisted over many decades. These logistical ...

Breast cancer affects millions of women worldwide and is the most commonly occurring cancer in women. While there are many different types of breast cancer, roughly 20% of all cases are ...

According to a recent peer-reviewed paper published in the journal of Cancer Medicine, the clinical trial failure rates for drugs treating major cancer types (non-small cell lung cancer, metastatic melanoma, non-Hodgkin’s ...

Strategy has become more important than ever when it comes to planning and executing global clinical trials given the quickly changing, unpredictable circumstances of the last year. These clinical trials are ...

Nearly a year after the first infection, much of Europe still remains under tough restrictions, as countries extend their lockdowns into Easter and further into April. Meanwhile, a third wave of ...